Sirolimus | Everolimus | P-Value | |
---|---|---|---|
3 months | |||
Decrease from baseline (mean ± SD, %) | 35.4 ± 16.2 | 42.0 ± 17.6 | 0.06 |
No. PR /Total No. patients (%) | 11/33 (33) | 42/91 (46) | 0.20 |
6 months | |||
Decrease from baseline (mean ± SD, %) | 38.1 ± 17.2 | 48.5 ± 20.6 | 0.01 |
No. PR /Total No. patients (%) | 12/32 (38) | 46/84 (55) | 0.10 |
12 months | |||
Decrease from baseline (mean ± SD, %) | 45.1 ± 13.9 | 56.7 ± 21.2 | 0.02 |
No. PR /Total No. patients (%) | 12/23 (52) | 34/49 (69) | 0.16 |
24 months | |||
Decrease from baseline (mean ± SD, %) | 52.5 ± 14.1 | 62.5 ± 15.3 | 0.09 |
No. PR /Total No. patients (%) | 6/10 (60) | 17/21 (81) | 0.38 |